Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MD-0901 (mesalazine) in pediatric patients with mildly to moderately active ulcerative colitis
jRCT2080223746Phase 3Completed
- Sponsor
- Mochida Pharmaceutical Co., Ltd.
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Salcrozine in autoimmune colitis, sponsored by Mochida Pharmaceutical Co., Ltd. Started Dec 2017; status: completed.
02
Drugs
Salcrozine
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT2080223746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223746.